1. Home
  2. REVB vs XXII Comparison

REVB vs XXII Comparison

Compare REVB & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • XXII
  • Stock Information
  • Founded
  • REVB 2020
  • XXII 1998
  • Country
  • REVB United States
  • XXII United States
  • Employees
  • REVB N/A
  • XXII N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • XXII Medicinal Chemicals and Botanical Products
  • Sector
  • REVB Health Care
  • XXII Health Care
  • Exchange
  • REVB Nasdaq
  • XXII Nasdaq
  • Market Cap
  • REVB 2.6M
  • XXII 2.1M
  • IPO Year
  • REVB N/A
  • XXII N/A
  • Fundamental
  • Price
  • REVB $3.05
  • XXII $1.08
  • Analyst Decision
  • REVB
  • XXII
  • Analyst Count
  • REVB 0
  • XXII 0
  • Target Price
  • REVB N/A
  • XXII N/A
  • AVG Volume (30 Days)
  • REVB 39.6K
  • XXII 603.9K
  • Earning Date
  • REVB 05-08-2025
  • XXII 05-13-2025
  • Dividend Yield
  • REVB N/A
  • XXII N/A
  • EPS Growth
  • REVB N/A
  • XXII N/A
  • EPS
  • REVB N/A
  • XXII N/A
  • Revenue
  • REVB N/A
  • XXII $23,869,000.00
  • Revenue This Year
  • REVB N/A
  • XXII $19.23
  • Revenue Next Year
  • REVB N/A
  • XXII $81.05
  • P/E Ratio
  • REVB N/A
  • XXII N/A
  • Revenue Growth
  • REVB N/A
  • XXII N/A
  • 52 Week Low
  • REVB $2.36
  • XXII $0.70
  • 52 Week High
  • REVB $60.80
  • XXII $226.80
  • Technical
  • Relative Strength Index (RSI)
  • REVB 49.28
  • XXII 47.15
  • Support Level
  • REVB $2.87
  • XXII $1.06
  • Resistance Level
  • REVB $3.32
  • XXII $1.26
  • Average True Range (ATR)
  • REVB 0.20
  • XXII 0.17
  • MACD
  • REVB 0.02
  • XXII 0.04
  • Stochastic Oscillator
  • REVB 47.18
  • XXII 49.25

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About XXII 22nd Century Group Inc.

22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.

Share on Social Networks: